SubsidieMeestersOils4cure: finding an effective drug to alleviate Refractory Epilepsy, one of the most severe symptoms in the pathology of Tuberous Sclerosis
OILS4CURE is developing YCJ-01, a medicinal cannabis extract-based drug aimed at managing refractory epilepsy in children with tuberous sclerosis.
Projectdetails
Introduction
OILS4CURE is a Spanish biotech company dedicated to the research, development, production, and commercialization of medicinal products based on a medicinal cannabis extract.
Project Overview
It is developing a drug to manage refractory epilepsy associated with tuberous sclerosis (YCJ-01) and another for leukodystrophies (YCJ-02), both of which are pediatric rare diseases.
Focus of the Project
This project only deals with the development of our first and most advanced therapy directed at tuberous sclerosis (TS).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.557.877 |
| Totale projectbegroting | € 2.225.538 |
Tijdlijn
| Startdatum | 1-12-2023 |
| Einddatum | 30-11-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- OILS4CURE SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Pannexin 1 – a novel target for pediatric orphan epilepsyPTI5803 is a first-in-class drug that specifically blocks the activated Pannexin 1 channel, effectively reducing seizures in ultra-resistant pediatric epilepsy while preserving cognitive functions. | EIC Accelerator | € 2.499.500 | 2023 | Details |
Development of a natural therapeutic treatment for late-stage lung cancer patientsCeltic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic painSea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment. | EIC Accelerator | € 2.499.035 | 2024 | Details |
EDV2209 – a Paradigm shift in the treatment of stroke.Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Pannexin 1 – a novel target for pediatric orphan epilepsy
PTI5803 is a first-in-class drug that specifically blocks the activated Pannexin 1 channel, effectively reducing seizures in ultra-resistant pediatric epilepsy while preserving cognitive functions.
Development of a natural therapeutic treatment for late-stage lung cancer patients
Celtic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy.
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.
EDV2209 – a Paradigm shift in the treatment of stroke.
Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Senolytics repurposing in childhood refractory epilepsiesEpiSen aims to develop a precision pharmacological strategy to selectively eliminate mutated cells in Focal Cortical Dysplasia, potentially reducing drug-resistant seizures in children. | ERC Proof of... | € 150.000 | 2023 | Details |
Targeting Epilepsy Ictogenesis Process Through Pannexin-1 ModulationThe project aims to develop a new generation of antiepileptic drugs targeting a novel mechanism to improve treatment for pharmacoresistant epilepsy patients. | ERC Proof of... | € 150.000 | 2022 | Details |
Preclinical development of a nanomedicine candidate for Fabry rare disease treatment to enter clinical phaseNano4Rare aims to advance the nanoGLA treatment for Fabry disease through preclinical development and GMP scale-up, while establishing a spin-off for commercialization of its innovative platform. | EIC Transition | € 2.498.563 | 2023 | Details |
Epilepsy Treatment Using Neuromodulation by Non-Invasive Temporal Interference StimulationThe EMUNITI project aims to develop a non-invasive, personalized brain stimulation device using temporal interference to diagnose and treat epilepsy, enhancing patient care and outcomes. | ERC Consolid... | € 1.996.925 | 2023 | Details |
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
Senolytics repurposing in childhood refractory epilepsies
EpiSen aims to develop a precision pharmacological strategy to selectively eliminate mutated cells in Focal Cortical Dysplasia, potentially reducing drug-resistant seizures in children.
Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation
The project aims to develop a new generation of antiepileptic drugs targeting a novel mechanism to improve treatment for pharmacoresistant epilepsy patients.
Preclinical development of a nanomedicine candidate for Fabry rare disease treatment to enter clinical phase
Nano4Rare aims to advance the nanoGLA treatment for Fabry disease through preclinical development and GMP scale-up, while establishing a spin-off for commercialization of its innovative platform.
Epilepsy Treatment Using Neuromodulation by Non-Invasive Temporal Interference Stimulation
The EMUNITI project aims to develop a non-invasive, personalized brain stimulation device using temporal interference to diagnose and treat epilepsy, enhancing patient care and outcomes.
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.